Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer
This study will evaluate the efficacy, safety and pharmacokinetics of capecitabine (2000 mg/m2/day by mouth \[po\], day 1 pm-day 15 am every 3 weeks \[q3w\]), oxaliplatin (130 mg/m2 intravenously \[iv\], day 1 q3w) and bevacizumab (7.5 mg/kg iv, day 1 q3w) in patients with advanced and/or metastatic colorectal cancer.
Colorectal Cancer
DRUG: Bevacizumab|DRUG: Oxaliplatin|DRUG: Capecitabine
Response rate: Response Evaluation Criteria in Solid Tumors (RECIST), event driven|Safety (Common Terminology Criteria for Adverse Events [CTCAE] version 3.0), throughout study
time to progression, event driven|overall survival, event driven|time to response, event driven|duration of response, event driven|concentrations of R340 and its metabolites, throughout study|concentrations of platinum, throughout study|concentrations of bevacizumab, throughout study|concentrations of vascular endothelial growth factor (VEGF), throughout study|concentrations of anti-bevacizumab antibody, throughout study
This study will evaluate the efficacy, safety and pharmacokinetics of Capecitabine (2000 mg/m2/day po, day 1 pm-day 15 am q3w), Oxaliplatin (130 mg/m2 iv, day 1 q3w) and Bevacizumab (7.5 mg/kg iv, day 1 q3w) in patients with advanced and/or metastatic colorectal cancer.